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AbstrACt
Objective Cardiovascular disease (CVD) is a leading cause 
of morbidity and mortality globally, and prevention of CVD 
is a public health priority. This paper aims to describe 
the perspectives of general practitioners (GPs) on the 
prevention of CVD across different contexts.
Design Systematic review and thematic synthesis of 
qualitative studies using the Enhancing Transparency of 
Reporting the Synthesis of Qualitative research (ENTREQ) 
framework.
Data sources MEDLINE, Embase, PsycINFO and CINAHL 
from database inception to April 2018.
Eligibility criteria for selecting studies We included 
qualitative studies on the perspectives of GPs on CVD 
prevention.
Data extraction and synthesis We used 
HyperRESEARCH to code the primary papers and 
identified themes.
results We selected 34 studies involving 1223 
participants across nine countries. We identified six 
themes: defining own primary role (duty to prescribe 
medication, refraining from risking patients’ lives, 
mediating between patients and specialists, delegating 
responsibility to patients, providing holistic care); 
trusting external expertise (depending on credible 
evidence and opinion, entrusting care to other health 
professionals, integrating into patient context); motivating 
behavioural change for prevention (highlighting tangible 
improvements, negotiating patient acceptance, enabling 
autonomy and empowerment, harnessing the power of 
fear, disappointment with futility of advice); recognising 
and accepting patient capacities (ascertaining patient’s 
drive for lifestyle change, conceding to ingrained habits, 
prioritising urgent comorbidities, tailoring to patient 
environment and literacy); avoiding overmedicalisation 
(averting long-term dependence on medications, 
preventing a false sense of security, minimising stress 
of sickness) and minimising economic burdens (avoiding 
unjustified costs to patients, delivering practice within 
budget, alleviating healthcare expenses).
Conclusions GPs sought to empower patients to prevent 
CVD, but consideration of patients’ individual factors was 
challenging. Community-based strategies for assessing 
CVD risk involving other health professionals, and decision 
aids that address the individuality of the patient’s health 
and environment, may support GPs in their decisions 
regarding CVD prevention.
IntrODuCtIOn 
Cardiovascular disease (CVD) is the leading 
cause of global morbidity and mortality, 
contributing to over 30% of deaths world-
wide.1–3 Cardiovascular events are highly 
preventable, through population and indi-
vidual-level interventions such as smoking 
cessation, weight reduction, physical activity 
and exercise, and blood pressure and lipid 
lowering therapies.4 
High-quality primary care is critical to CVD 
prevention,5 6 due to the opportunity to assess 
risks and to provide lifestyle and pharma-
cological interventions. It is widely recom-
mended that primary prevention of CVD be 
based on the assessment and management 
of absolute risk,7 8 but there is evidence of 
research practice gaps, with inconsistencies 
in the use of risk assessment tools and guide-
lines,8–10 advice on lifestyle interventions and 
prescription of preventive medications.11 12
While these shortfalls are likely to be due 
to many factors5 13 including challenges in 
strengths and limitations of this study
 ► Qualitative studies conducted in range of set-
tings and populations were synthesised to gen-
erate a more comprehensive understanding of 
decision-making and approaches to cardiovascular 
disease prevention among general practitioners.
 ► Some studies did not specify whether an absolute 
risk assessment or individual risk factor approach 
was used, and differences between perspectives on 
primary and secondary prevention were unclear.
 ► Non-English articles were excluded, which may limit 
the transferability of the study’s findings.
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managing diverse patient populations and variability 
in patient motivation,14 more detailed data on why 
this occurs at the healthcare provider level are limited, 
hindering practical strategies for improvement. General 
practitioners (GPs) play a key role in assessment and 
management of CVD risk and qualitative studies have 
elucidated their perspectives on primary and secondary 
prevention of CVD. A synthesis of qualitative studies can 
generate a more comprehensive understanding of the 
reasons for decisions and approaches to CVD prevention 
across different settings and populations in primary care. 
We aimed to describe the spectrum of GP perspectives to 
inform strategies that may address concerns, uncertain-
ties and the challenges in CVD prevention, to support 
decisions and implementation of evidence-based strate-
gies for the prevention of CVD and improved healthcare 
outcomes.
MEthODs
The reporting of this study follows the Enhancing Trans-
parency of Reporting the Synthesis of Qualitative research 
(ENTREQ) framework15 and the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses) checklist16 (online supplementary file 1).
selection criteria
Qualitative studies on the perspectives of GPs regarding 
the primary and secondary prevention of CVD were 
eligible for inclusion. GPs were defined as physicians who 
assumed responsibility for providing ‘continuing and 
comprehensive medical care to individuals, families and 
communities’17 and included primary care physicians and 
family practitioners. Studies published in peer-reviewed 
journals and doctoral dissertations were included. We 
excluded quantitative surveys, epidemiological studies 
(eg, randomised trials), non-primary research articles 
(eg, reviews), clinical guidelines, economic studies and 
non-English articles to minimise misinterpretation in 
translation.
Data sources and searches
We used a sensitive search strategy, which is provided in 
online supplementary file 2. Searches were conducted 
in MEDLINE, Embase, PsycINFO and CINAHL from 
database inception to 15 April 2018. We searched the 
ProQuest Dissertation and Thesis database, British Library 
Electronic Digital Thesis Online Service and the Europe 
E-theses Portal for doctoral dissertations. Primary care 
journals, Google Scholar and reference lists of included 
studies were also searched. Titles and abstracts were 
screened by IJ who excluded studies that did not meet the 
inclusion criteria. The full texts of the remaining articles 
were assessed for eligibility.
Assessment of study reporting
To evaluate comprehensiveness and transparency 
of reporting in each study, we used the COREQ 
(Consolidated Criteria for Reporting Qualitative Health 
Research). The framework included reporting items 
specific to the research team, study methods, context of 
the study, analysis and interpretations. Three reviewers 
(IJ, AJ and CSH) independently assessed each study, and 
any inconsistencies were resolved by discussion.
synthesis
Using thematic synthesis,18 we entered all the partici-
pant quotations and text from the ‘Results’ section of 
each paper into the software HyperRESEARCH (version 
3.0.3; ResearchWare, Randolph, Massachusetts, USA) 
to code the data. Author IJ read each article line-by-line 
and coded text into inductively derived concepts that 
reflected GPs’ perspectives on the prevention of CVD. 
Author IJ translated concepts within and across studies 
by interpreting the data from the primary studies and 
coded text to existing concepts (that had been identified 
in previous studies), or by creating a new concept (that 
was not identified in previous studies) when necessary. 
Similar concepts were grouped into themes. The prelim-
inary themes were discussed with the research team 
(AJ, AT) who also read the included studies. This form 
of investigator triangulation ensures that the full range 
and depth of data reported in the original studies are 
captured in the analysis. We identified conceptual links 
and developed a thematic schema. We cross-tabulated the 
themes with primary and secondary prevention strategies 
for CVD (eg, medications, lifestyle or behavioural change, 
risk assessment tools and service delivery models).
Patients and public involvement
Patients were not directly involved in this systematic 
review of GPs’ perspectives on prevention of CVD.
rEsults
literature search
Of the 7405 articles identified in the search, we included 
34 studies, involving more than 1223 GPs (one study did 
not report the number of participants, figure 1). The char-
acteristics of the studies are provided in table 1. Across 
the studies, interviews, focus groups and questionnaires 
with open-ended questions were used to collect the data.
Comprehensiveness of reporting in included studies
The comprehensiveness of reporting varied, with studies 
addressing 6 to 19 of the 24 criteria for reporting of 
qualitative studies (table 2). The participant selection 
strategy and the participant characteristics were reported 
in all 34 (100%) studies. The duration and the venue of 
data collection was specified in 20 (59%) and 10 (29%) 
studies, respectively. Twenty-eight (82%) studies reported 
researcher triangulation, and 17 (50%) studies reported 
on their use of software to facilitate data analysis. Quota-
tions were provided in 30 (88%) studies.
synthesis
We identified six themes: defining own primary role; 
trusting external expertise; motivating behavioural 
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change for prevention; recognising and accepting 
patient capacities; avoiding medicalisation and mini-
mising economic burdens. Selected quotations for each 
theme are provided in table 3. The relationships among 
themes are shown in figure 2. Figure 3 shows a matrix of 
the themes that related to each CVD prevention strategy. 
Most studies did not specify if perspectives related to 
primary or secondary prevention or a specific population 
(eg, high risk); however where possible, these have been 
delineated in the synthesis.
Defining own primary role
Duty to prescribe medication
Some GPs believed their core role, as a physician, was 
to ‘offer the tablets’19 and prescribe medicines, whereas 
counselling patients to make lifestyle changes was a 
secondary focus. Preventive medication was perceived by 
some as being less imposing than lifestyle changes, as it 
would not impede on patients’ ‘quality of life’.20
Refraining from risking patients’ lives
Some GPs were highly cautious and wary of putting 
patients’ lives at risk such that they exercised absolute 
‘vigilance’21 and advised patients to take preventive 
medications regardless of their risk of CVD. This was 
seen as more effective in preventing CVD-related death 
compared with recommendations for lifestyle change—
‘[GPs] would always recommend preventative medication 
to their patients,… “I don’t take the slightest risk with 
someone else’s life”’.22
Partnering with specialists
As patients at high risk of CVD often had comorbid-
ities, some GPs ‘co-managed’21 their patients with 
specialists. ‘Working together’21 with specialists meant 
reinforcing, to the patient, the specialist’s advice and 
GPs believed that this would strengthen cohesive care 
for the patient.
Delegating responsibility to patients
Some GPs defined their role as an ‘influencer’23 in their 
patients’ self-motivation and management. They could 
only provide information but believed it was ultimately 
the patients’ duty to make lifestyle changes or take their 
medication. Enforcing medications and behavioural 
change on patients was deemed unethical and not within 
their professional purview, and seen as ‘presumptuous to 
make such strong demands’.20
Providing holistic care
Some GPs emphasised their desire to take on a gener-
alist role by providing comprehensive care and being 
Figure 1 Search results. CVD, cardiovascular disease; GP, general practitioner; QOL, quality of life.
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‘carers for the total patient,’ which included taking 
responsibility for lifestyle, nutrition education and 
prescribing medicine. Some GPs considered that 
this also involved ‘creating a positive expectation’,20 
enabling the patient to feel optimistic about the 
preventive strategy outcomes, which was important 
for patient motivation.
trusting external expertise
Depending on credible evidence and opinion
Some GPs trusted research evidence and expert opinion 
to feel secure about their decisions. Guidelines, risk 
assessment tools and ‘editorials in the (British Medical 
Journal) BMJ’24 were seen to minimise room for human 
error and were more reliable than their own judge-
ment—‘I’m comfortable to be guided by the experts 
rather than try and invent too much on what might be 
dodgy assumptions on my part.’25
Entrusting care to other health professionals
Educating patients about diet and nutrition to prevent 
CVD was regarded by some as being ‘outside their interest 
and expertise’23 and believed that dieticians or other clini-
cians were better able to inform patients about lifestyle 
Table 2 Completeness of reporting in the included studies
Item Studies reporting each item No of studies (%)
Personal characteristics
  Interviewer/facilitator identified 19 20 23–25 27 30 32–34 40 66 70 78 79 15 (44)
  Experience or training in qualitative research 27 32 33 66 81 5 (15)
Relationship with participants
  Relationship established prior to study commencement 26 32 40 66 74–76 82 8 (24)
Participant selection
  Selection strategy (eg, snowball, purposive, convenience, 
comprehensive)
19–34 40 66–82 34 (100)
  Method of approach or recruitment 19–23 25–28 30–34 40 66–76 78–82 31 (91)
  Sample size 19–34 40 66–82 34 (100)
  Number and/or reasons for non-participation 20 21 24–30 32–34 66 69–73 75 78–80 22 (65)
Setting
  Venue of data collection 19 26 40 66 68 74–77 82 10 (29)
  Presence of non-participants (eg, clinical staff) 26 31 34 74 82 5 (15)
  Description of the sample 19–34 40 66–76 79–82 32 (94)
Data collection
  Questions, prompts or topic guide 19–34 40 66–76 78–82 33 (97)
  Repeat interviews/observations 22 23 31 34 73 80 6 (18)
  Audio/visual recording 20 21 23–34 40 66–68 70 71 73–79 81 82 30 (88)
  Field notes 26 28 34 68 70 71 79 7 (21)
  Duration of data collection (interview or focus group) 20 21 25 26 28 31 34 66 67 72–82 20 (59)
  Protocol for data preparation and transcription 19–28 30–34 40 66–70 72–77 79–82 31 (91)
  Data (or theoretical) saturation 21 22 25 27 32–34 66 67 76 79 80 12 (36)
Data analysis
  Researcher/expert triangulation (multiple researchers 
involved in coding and analysis)
19–21 23–34 40 66 67 71 73–80 82 28 (82)
  Derivation of themes or findings (eg, inductive, constant 
comparison)
19–34 40 66–68 71–82 32 (94)
  Use of software (eg, NVivo, HyperRESEARCH, Atlas.ti) 20 21 23 26 28–30 40 66–68 70 73 76–78 80 17 (50)
  Participant feedback on findings 21 23 31 32 73 79 6 (18)
Reporting
  Participant quotations or raw data provided (picture, diary 
entries)
19–22 24–34 40 66 67 70–75 77–82 30 (88)
  Range and depth of insight into participant perspectives 
(thick description provided)
19–34 40 66–68 73–75 78–81 27 (79)
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l t
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d
 c
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e 
it 
in
 y
ou
r 
m
in
d
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he
n 
d
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e 
ho
w
 h
ar
d
 y
ou
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re
 g
oi
ng
 t
o 
ch
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e 
ea
ch
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f t
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se
 r
is
k 
fa
ct
or
s 
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ol
e 
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f] 
m
ul
tiv
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m
in
s 
is
 v
er
y 
im
p
or
ta
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, a
s 
d
ie
t 
[is
] o
ft
en
 in
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eq
ua
te
, a
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 [i
t 
is
] v
er
y 
d
iffi
cu
lt 
to
 g
et
 t
hi
s 
ag
e 
gr
ou
p
 t
o 
ch
an
ge
. 
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 s
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in
g 
th
at
 I 
se
nt
 a
 v
er
y 
m
ot
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at
ed
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ye
ar
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 t
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] d
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ia
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 c
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to
 c
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vi
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em
 t
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t 
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o 
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h 
an
d
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 e
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ou
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in
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to
 c
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vi
nc
e 
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e 
th
at
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ut
 t
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s 
th
at
 t
ak
e 
it 
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 m
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e 
p
ro
gr
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…
 t
he
y 
fe
el
 p
os
iti
ve
 …
 e
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ou
ra
ge
d
 …
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ar
d
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 m
ot
iv
at
ed
 t
o 
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go
in
g.
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 w
an
t 
so
m
eh
ow
 t
o 
gi
ve
 t
he
m
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et
hi
ng
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iti
ve
 t
o 
cl
in
g 
to
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 t
ha
t 
if 
I c
an
 d
o 
th
is
 a
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 t
ha
t 
an
d
 I 
ca
n 
st
op
 s
m
ok
in
g 
or
 I 
ca
n 
go
 d
ow
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in
 w
ei
gh
t 
or
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 I 
ca
n 
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a 
lit
tle
 m
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e 
p
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 a
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iv
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ill
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 w
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ou
 c
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 s
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w
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 p
at
ie
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 t
he
 r
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k 
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ge
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 b
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od
 p
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ur
e 
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ch
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ch
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 p
ow
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l t
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”7
1
20
 2
7 
71
N
eg
ot
ia
tin
g 
p
at
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is
 a
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ar
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 a
 d
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hi
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it 
ha
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 b
e 
so
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ng
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ur
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ge
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el
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, b
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 o
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d
ie
t 
an
d
 
ex
er
ci
se
”4
0
“C
le
ar
ly
 t
he
 e
vi
d
en
ce
 a
ro
un
d
 t
he
 w
or
ld
 is
 t
ha
t 
th
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p
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 p
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iti
on
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at
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 r
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at
io
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 is
 t
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 in
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 in
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 s
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te
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. T
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 c
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 t
he
re
’s
 t
ru
st
. Y
ou
 g
et
 b
et
te
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ou
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om
es
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nd
 p
ar
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of
 t
ha
t 
is
 t
ha
t 
p
eo
p
le
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 m
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e 
w
ill
in
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to
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it 
to
 t
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at
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p
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ns
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 t
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p
eo
p
le
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 b
it 
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d
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p
in
g 
th
em
 t
o 
un
d
er
st
an
d
 t
ha
t 
th
ey
 c
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 c
on
tr
ol
 t
he
ir 
ris
k 
fa
ct
or
s 
ei
th
er
 w
ith
 o
r 
w
ith
ou
t 
m
ed
ic
at
io
n 
an
d
 t
he
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I t
hi
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 t
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t 
gi
ve
s 
th
em
 a
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f e
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 c
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 d
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ar
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in
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ar
d
 m
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r, 
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 a
 v
er
y 
sc
ar
y 
p
er
so
n 
…
 a
nd
 I 
w
on
’t 
le
t 
yo
u 
ge
t 
aw
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 w
ith
 t
hi
ng
s.
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ut
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’s
 o
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au
se
 I 
ca
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 a
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 b
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au
se
 
I w
an
t 
go
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 t
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ng
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r 
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 p
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so
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 t
hi
ng
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p
en
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em
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 if
 y
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 d
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 d
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at
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 r
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 C
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at
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p
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b
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b
er
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f p
at
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 t
hi
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 t
he
y 
ne
ve
r 
w
an
t 
to
 h
ea
r 
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in
 t
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fir
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 p
la
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in
g 
he
ar
d
 it
 t
he
y 
ha
ve
 n
o 
in
te
nt
io
n 
of
 d
oi
ng
 a
ny
th
in
g 
ab
ou
t 
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 a
m
 n
ot
 c
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vi
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ed
 t
ha
t 
w
e 
d
o 
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 m
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lik
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 t
hi
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 w
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d
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am
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d
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 c
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 b
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 m
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fin
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 c
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 p
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ng
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 d
is
cu
ss
io
n 
w
ith
 p
eo
p
le
 t
o 
fin
d
 o
ut
 h
ow
 m
uc
h 
th
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at
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 p
at
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to
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 d
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 w
ha
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 d
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 m
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at
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yo
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 r
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h 
le
ve
ls
, a
nd
 y
ou
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 c
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iv
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w
ill
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 b
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ve
ry
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so
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so
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 b
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e 
p
ha
rm
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 t
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 t
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b
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 b
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at
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d
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th
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al
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s 
it 
is
 v
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y 
d
iffi
cu
lt 
to
 c
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of
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th
er
 p
at
ie
nt
s 
ha
d
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im
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ta
nt
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D
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 c
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 d
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in
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 m
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 r
is
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w
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il 
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at
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b
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 m
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b
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d
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cu
lt 
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 g
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 r
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lm
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 p
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 c
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ve
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 d
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 c
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e 
ris
k 
ca
lc
ul
at
or
 a
nd
 s
ee
 h
ow
 t
hi
ng
s 
ca
n 
ch
an
ge
. W
he
re
as
 if
 y
ou
’v
e 
go
t 
…
 s
om
eo
ne
 w
ho
 is
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yo
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ed
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b
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lit
tle
 b
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…
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 in
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r 
d
es
cr
ip
tio
n 
of
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an
d
 c
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ng
in
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ot
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d
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l c
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 b
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 m
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b
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 p
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 b
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ng
 
yo
un
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is
 w
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I t
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 t
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b
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 p
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at
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 t
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”2
0
“A
b
ov
e 
al
l t
o 
gi
ve
 u
p
 s
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ou
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ot
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…
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b
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rd
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 d
ie
t,
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m
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n 
p
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p
le
 s
ay
 
‘o
h 
it 
d
oe
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’t 
m
at
te
r, 
ta
ke
 t
he
 t
ab
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ts
 I 
ca
n 
d
o 
an
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hi
ng
 I 
lik
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. T
ha
t’s
 n
ot
 t
ru
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yo
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ha
ve
 t
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ve
 a
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oo
d
 d
ie
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el
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ng
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b
le
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he
 t
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le
ts
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 is
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ot
 g
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 t
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fix
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ve
ry
th
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d
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changes. Some GPs were enthusiastic about a team-based 
approach to prevention involving trained practice nurses 
and lifestyle advisors due to time constraints in their own 
consultations.26 For patients with comorbidities, some 
GPs considered specialists (eg, psychiatrists, cardiolo-
gists) to have more authority in educating their patients, 
as they had better knowledge of the patient’s condition 
and medication.
Integrating into patient context
Some GPs considered the patient’s family history and 
background when determining prevention strate-
gies. They advocated the use of ‘human judgement,’ 
which incorporated ‘emotional, political and logis-
tical’19 considerations rather than accepting risk 
scores unconditionally. Others were unwilling to use 
risk scores to estimate pretreatment risk due to ambi-
guity of current guidelines regarding unique patient 
circumstances.
Motivating behavioural change for prevention
Highlighting tangible improvements
Some GPs used visual prompts to demonstrate to their 
patients the direct improvements in health and decrease 
of risk scores, which could be achieved through changes 
to lifestyle. They believed this approach encouraged 
patients to make active changes by giving them ‘some-
thing positive to cling to’.27
Negotiating patient acceptance
When developing a strategy for preventing CVD, some 
GPs perceived that compromise was necessary in encour-
aging patients to cooperate. An explicit discussion and 
consideration of the patient’s goals and priorities was 
seen to encourage patients to ‘work with the doctor, not 
against the doctor’28 which built trust. Some GPs copro-
duced a strategy with the patient that was feasible for the 
patient’s own situation.
Enabling autonomy and empowerment
Some GPs noted that patients with a lower risk of CVD were 
highly anxious about their risk factors and responded by 
giving patients reassurance and control over their medi-
cation and lifestyle prevention strategies. GPs perceived 
that patients who had a sense of autonomy and empow-
erment over their bodies felt more secure and willing to 
manage their risk factors.
Harnessing the power of fear
When managing patients at high risk of CVD, some 
GPs felt that scaring patients into action was neces-
sary and warranted. They believed that an emphasis 
on the consequences of disregarding and being 
non-adherent to prevention strategies motivated 
patients to accept their advice, telling their patients 
‘if you don’t want that kind of scenario you do what 
I tell you’.27T
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Disappointment with futility of advice
When patients were seen to lack motivation and had 
‘no intention of doing anything’, some GPs perceived 
that their efforts to encourage the patient’s uptake of 
prevention strategies were a ‘waste of time’. In failing 
to motivate patients, GPs questioned their ability to 
prevent CVD in their patients, being ‘[un]convinced 
that we do as much good as we like to think we do’.29
recognising and accepting patient capacities
Ascertaining patients’ drive for lifestyle change
Some GPs felt they had to be realistic about their patients’ 
desires to modify their daily lives, including changes to 
diet, physical activity and commencing a medication 
regimen. When patients seemed unwilling, GPs refrained 
from encouraging lifestyle changes or prescribing drugs 
to save their own time and resources.
Conceding to ingrained habits
Some GPs believed that patients who had established 
long-term lifestyle patterns in life (particularly patients 
who were obese and elderly) were unlikely to alter their 
habits (eg, smoking, diet), and so did not encourage life-
style changes. They concluded that ‘medications are the 
only hope’30 for patients who they believed were unable 
to adopt preventive behaviours.
Prioritising urgent comorbidities
In patients with comorbidities (eg, diabetes, mental 
illness), some GPs chose to delay prescribing strategies 
for CVD prevention to minimise the stress in patients of 
having to contend with multiple treatments. They focused 
on the patient’s primary condition until they felt that the 
patient was emotionally and mentally prepared to discuss 
CVD prevention. For patients on medication for another 
disease, GPs were hesitant to prescribe more medication 
as they expected that the complexities of polypharmacy 
reduced overall adherence.
Tailoring to patient environment and literacy
Some GPs recognised that health literacy varied across 
the patient population and communicated the level 
of risk of CVD by using various approaches (eg, statis-
tics, visual graphs, simpler words) according to the 
patient’s educational attainment and socioeconomic 
status. GPs took into account the patient’s environment 
to ensure feasibility of enacting prevention strategies, 
for example, ‘[the patient’s neighborhood was not] 
Figure 2 Matrix of prevention strategies and themes.
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conductive to making lifestyle behavioural changes’ 
with ‘multiple fast food outlets’.31
Avoiding overmedicalisation
Averting long-term dependence on medications
Some GPs were concerned that most patients would 
be inclined to opt for medications as an immediate 
and easy solution, rather than make lifestyle changes. 
This was attributed to the marketing and widespread 
advertising of medications in the general public. 
They believed that giving young patients or patients 
who were not at high risk a lifetime prescription of 
medicine for preventive purposes should be avoided 
by encouraging lifestyle changes instead, to prevent 
a dependence on medications when it was not abso-
lutely necessary.
Preventing a false sense of security
Some GPs were cautious and critical of ‘medicaliz[ing] 
an unhealthy lifestyle’20 as this encouraged patients 
to continue with their harmful habits (eg, sedentary 
lifestyle, poor diet, smoking) and ‘forget about their 
lipid-lowering diet’.32 They noted that patients trusted the 
medicine to reduce their risk of CVD in spite of their life-
style choices. With reference to medications and lifestyle 
modification, GPs believed that ‘you cannot do one thing 
without the other’33 and refrained from overprescribing 
medicine to prevent patients from believing that they 
were ‘immortal’.32
Minimising stress of sickness
Regardless of the patient’s level of risk for CVD, some GPs 
urged to avoid instilling unnecessary anxiety in patients, 
as ‘fear becomes a major problem’29 and in turn elevates 
their risk further. They were hesitant to ‘turn individuals 
into patients’19 in the context of primary prevention for 
patients with low risk, as tests and preventive medications 
heightened their anxiety about their health. For example, 
a GP expected that a patient with high cholesterol would 
be conscious of their condition, and alerting them to 
their risk of heart attack would ‘get themselves into more 
of a state’.27
Minimising economic burdens
Avoiding unjustified costs to patients
Some GPs especially in low socioeconomic regions like 
Guatemala were mindful of the economic burden of 
long-term medication on patients and thus prescribed 
medications only for patients at high risk as determined 
by their cholesterol or blood pressure. Some were also 
conscious and expressed concerns about the commercial 
interests of pharmaceutical companies—‘95% of treat-
ment with statins is wasted’ and ‘fuelled by the interests of 
the pharmaceutical industry’.22 However, others believed 
in the long-term cost-effectiveness of preventive medicine 
in minimising the potential for incurring costs for treat-
ment of CVD.
Figure 3 Thematic schema.
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Delivering practice within budget
Some GPs in studies conducted in the UK and New Zealand 
were careful not to exceed their budget for drug prescrip-
tions, and they were conscious of the limitations of funding 
available for their practice, which contended with external 
pressures (from pharmaceutical companies, health adver-
tising) to offer drug treatment. GPs were more inclined to 
prescribe medicine for secondary prevention of CVD or 
for primary prevention in patients with a high risk of CVD 
to ensure an adequate budget for other patients in their 
practice.
Alleviating healthcare expenses
Some GPs perceived preventive procedures (blood tests, 
routine checks) to be a healthcare burden when the 
whole population was screened regardless of risk levels or 
immediate illnesses. This placed them under increasing 
pressure due to a greater demand for general screening. 
They were mindful of the resources and nurse time as well 
as their own time spent screening for risks for primary 
prevention in low-risk patients, as this detracted from 
resources available for patients who were ‘actually ill’.29
DIsCussIOn
Primary care healthcare providers believed that patients 
needed to be empowered to continue with medica-
tions and be motivated to make lifestyle changes for the 
prevention of CVD, but were challenged by the complexi-
ties of considering the patient’s cognitive capacities, prac-
tical circumstances and health status. Some articulated a 
professional and ethical duty, to prescribe medications 
for the prevention of CVD and subsequently minimise 
the risk of future CVD events that could be prevent-
able, and to avoid taking any responsibility for risking 
the patients’ lives. However, some had concerns about 
prescribing patients long-term medications, particularly 
in the context of primary prevention and among patients 
who were not deemed to be at high risk of CVD.
Providers considered preventive strategies in the 
context of tensions between respecting patient autonomy 
and being too intrusive and paternalistic in recom-
mending behavioural change. In making decisions about 
prescribing medication therapy, they considered the 
economic impact on their local practice (particularly in 
the UK) and broader healthcare costs, and specifically 
in terms of prioritising resources for patients with more 
urgent illnesses than to those who were asymptomatic 
with risk factors.
Differences in perspectives among GPs were apparent, 
in part reflecting their region of practice, sociodemo-
graphics of their patient population and the use of an 
absolute CVD or individual risk factor approach. In 
studies conducted in New Zealand, the UK and Guate-
mala, GPs deliberated on the financial burden of 
screening in the general population for primary preven-
tion and costs of medications incurred to their patients 
as well as their own practice. Some GPs who practised in 
low socioeconomic areas believed that advising lifestyle 
changes, particularly in terms of diet, were futile as they 
believed that patients had limited access to healthy food 
in their local area. In earlier studies, GPs expressed more 
hesitation about prescribing medications, when this was 
not yet common practice nor widely recommended for 
primary prevention.20 25 34 The majority of studies did not 
specify whether GPs used an absolute risk or individual 
risk factor approach to management, and did not detail 
the risk profile of their patients (ie, level of risk of CVD) 
when discussing preventive strategies. The concept of 
absolute risk was explicitly discussed in 17 (53%) studies, 
and these studies were focused on GPs perspectives on 
tools for assessing absolute risk for CVD prevention.
Our study provides insights on the variability in deci-
sions and approaches to CVD prevention among GPs. 
Approximately half of GPs use cardiovascular risk calcu-
lators and clinical guidelines,35 and those who do not use 
them have cited reasons including difficulties in using 
and interpreting the tools, and lack of applicability to 
their patient population in terms of age, socioeconomic 
background and family history. Our findings indicate that 
GPs may prefer to make their own judgement of indi-
vidual risk factors acquired through experience rather 
than using absolute risk assessment tools.
While a vast majority of GPs would recommend drug 
prescription where appropriate, this does not necessarily 
translate into rates of actual prescription. For example, a 
study in the UK found that only 42% of patients eligible 
for lipid lowering drugs were prescribed them.12 36 Our 
findings suggests that GPs’ decisions to prescribe medica-
tion can be influenced by their perception of how likely 
the patient is willing to commence the regimen and how 
likely they are to adhere to medications. Also, some GPs 
expressed reluctance to ‘medicalise’ unhealthy lifestyles 
and foster a false sense of security in patients through 
medication.
A recent study found that more than half of GPs rated 
their ability to motivate behavioural change for CVD 
prevention as being ‘not good’, particularly for patients 
who were over 65, male or obese.37 Our findings indicate 
that GPs believe that it may be difficult to motivate change 
in patients with established lifestyle habits, particularly in 
older or obese patients, and need a more immediate solu-
tion such as medication.
The themes identified in our synthesis reflect find-
ings from studies of GPs’ perspectives on the prevention 
of other chronic conditions such as diabetes. In a study 
on the prevention of type 2 diabetes,38 GPs questioned 
their role and obligation in preventive care, where some 
expressed frustration at the societal pressure placed on 
them to screen patients for health risks despite the lack 
of funding and resources. They believed that education 
about healthy lifestyles should be delivered via schools 
and community programmes. Similarly, some GPs felt 
pressure from pharmaceutical companies to prescribe 
medication despite a limited budget for prescriptions 
within their own practice.29 39 40 Instead, they preferred 
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assistance from and delegation to specialists, nursing staff 
and dieticians. In the context of diabetes, GPs were also 
concerned that resources in general practice were increas-
ingly directed towards management of diabetes, leading 
to the specialisation of staff (nurses, GPs) and a phasing 
out of general practice nurses. GPs similarly wanted to 
retain a generalist role in CVD prevention and provide 
comprehensive care involving all aspects of preventative 
health rather than a single focus on prevention of CVD.20
Our synthesis captured a broad range of the perspec-
tives of GPs across different settings, and included atti-
tudes pertaining to various CVD prevention strategies. 
However, there are some potential limitations. We were 
unable to differentiate whether GPs were using an abso-
lute risk assessment or an individual risk factor approach, 
and whether perspectives were different in primary and 
secondary prevention, as these were not specified in most 
studies. Non-English articles were excluded, which could 
limit the transferability of the study’s findings. We were 
unable to assess the prevalence of each theme. System-
atic reviews of qualitative studies are designed to describe 
the range and depth of perspectives, and cannot quantify 
the prevalence of themes. However, table 3 include refer-
ences of the studies that contributed to each theme.
Based on our findings, we suggest adapting or devel-
oping risk assessment tools that incorporate patient 
factors, motivating behavioural change in patients 
and ensuring adoption of cost-effective strategies in 
prescribing medications. In preventive care, treatment of 
individual risk factors may still be used over absolute risk 
assessment, with low uptake of risk assessment tools.7 8 41 
Greater use of absolute risk assessment tools and guide-
lines that explicitly address patient factors such as socio-
economic status, family history and lifestyle choices may 
be more useful for GPs.39 42 43 Motivating adherence for 
both behavioural and pharmaceutical changes remains 
a challenge for GPs. Despite behavioural change being 
a highly cost-effective prevention strategy,44 45 patient 
motivation and adherence to lifestyle advice is a barrier 
to preventive care.46–49 A multifaceted approach in 
a primary care setting involving supervised exercise 
sessions, follow-up calls and timed medication reminders 
in addition to current GP services can improve patients’ 
adherence to prescribed medication and behavioural 
changes, while addressing barriers such as time and 
resource constraints for GPs. Recent lifestyle interven-
tion trials in a primary care setting revealed reductions 
in individual risk factors (blood pressure, obesity, choles-
terol), and improvements in total mortality as well as fatal 
and non-fatal cardiovascular events.50–55 Recent reviews 
of interventions revealed that most of those resulting 
in long-term patient adherence to behavioural changes 
included other healthcare professionals such as nurses, 
pharmacists and therapists, involving more convenient 
care (for individual patients), reinforcement of lifestyle 
advice, family and psychological therapy, telephone 
follow-up and technological supportive care (Fitbits, text 
messaging, apps).56–59
Our study also identified some research gaps, including 
perspectives on total (absolute) or individual (rela-
tive) risk assessment, effects of long-term dependence 
on medication, guidelines for prescription in primary 
care and the issues of gender and family support. When 
referring specifically to absolute CVD risk, some GPs 
discussed absolute risk assessment tools, but did not 
talk in depth about the concept of absolute risk and 
how they considered this in their decision-making and 
practice. A distinction between assessing absolute risk 
and individual risk factors is important in allowing for 
a more consistent and evidence-based evaluation for 
treatment plans. Current studies also did not address 
primary prevention in depth specifically, and some GPs 
expressed hesitation when providing primary preven-
tive care to patients as they questioned the necessity 
for medication in asymptomatic patients and based on 
theoretical risk. Greater awareness of and adherence to 
evidence-based guidelines on medications for asymptom-
atic patients and risk factors may improve consistency of 
evaluating and managing CVD risk in patients.5 7 There 
was also a lack of data on GP’s reflections on the role 
of family support. Family members can facilitate and 
support behavioural change by encouraging preventative 
lifestyle choices and reminding patients to take medi-
cations.60 61 On the other hand, family members may 
dissuade patients from following a healthy lifestyle.61 62 
There was also limited data on gender. CVD has been 
considered a ‘man’s disease’, as the prevalence of CVD 
is higher in men compared with women until the age of 
75 years.63 64 This has given rise to concerns about under-
estimating the risk of CVD in women, and it has been 
shown that weight loss programmes, for example, are 
recommended more frequently to men than women.63 65 
Women may not always present with typical chest pain 
in myocardial infarctions and coronary events, more 
commonly presenting with dyspnoea and fatigue. This 
makes early recognition and prevention of CVD more 
difficult in women.64 65 Women can also present later 
than men and with more comorbidities, leading to misdi-
agnosis and poorer health outcomes.65 Women are more 
likely to delay seeking treatment, attribute symptoms to 
non-cardiac causes and perceive pain levels differently to 
men. A combination of these factors can lead to delayed 
treatment and implementation of preventive measures.65
GPs believed that empowering patients to prevent 
CVD through adherence to lifestyle and medications was 
needed, but found it challenging to motivate behavioural 
change. Some considered that clinical decision-making 
for CVD prevention involved the patients’ life stage and 
circumstances, capacity for self-management and their 
environment, which were not addressed in risk assess-
ment and decision-making tools. Greater availability and 
adaptability of evidence-based strategies for assessing and 
managing CVD risk, including behavioural change in 
patients, may support decisions and implementation of 
CVD prevention activities among GPs.
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